
Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510



01 FEB 14 PH 1: 26

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

DC 20002 USA
1916 (optional) 5. Senate (D.# 36792-191
6. House ID # 30115007
on Date 01/01/2001 11. No Lobbying Activity (er Line 12 OR Line 13
13. Organizations
EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 🗍
\$10,000 or more:
Expenses (nearest \$20,000) 14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options. If Method A. Reporting amounts using LDA definitions only Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
Method C. Reporting amounts under section 162(c) of the Internal Revenue Code

engaged in tobbying on behalf of the client during information as requested. Attach additional page(s 5. General issue area code <u>CPT</u> (one 6. Specific Lobbying issues	e per page) Act., Oppose provision in section 116 that undermine intellectual property for the control of the
ingaged in tobbying on behalf of the client during information as requested. Attach additional page(s. S. General issue area code <u>CPT</u> (one 6. Specific Lobbying issues H.R. 434, African Growth & Opportunity U.S. pharmaceuticals abroad. 7. House(s) of Congress and Federal agencies of Department of Commerce, Patent and Tra House of Representatives	the reporting period. Using a separate page for each code, provide () as needed. per page) Act., Oppose provision in section 116 that undermine intellectual property for the content of
 Specific Lobbying issues H.R. 434, African Growth & Opportunity U.S. pharmaceuticals abroad. House(s) of Congress and Federal agencies of Department of Commerce, Patent and Tra House of Representatives 	Act., Oppose provision in section 116 that undermine intellectual property for
H.R. 434, African Growth & Opportunity U.S. pharmaceuticals abroad. 7. House(s) of Congress and Pederal agencies of Department of Commerce, Patent and Tra House of Representatives	ontacted . Check if None
Department of Commerce, Patent and Tra House of Representatives	ontacted .
Department of Commerce, Patent and Tra House of Representatives	ontacted . Check if None demark Office
Department of Commerce, Patent and Tra House of Representatives	ontacted . Check if None demark Office
 Name of each individual who acted as a lobby Name 	rist in this issue area Covered Official Position (if applicable) New
Baxter, Edward	No
DeConcini, Dennis	No.
Martin, Jack	
Parry, Thomas	No.
Romani, Romano	No.
Skladany, Linda	No No
	180
Interest of each foreign entity in the specific is Glaxo Wellcome ple NONE	sues listed on line 16 above Check if None
≥nature	Date 02/13/2001
inted Name and Title Romane Romani - President	

Registrant Name:	Parry and Romani Associates, Inc.		
Client Name:	Glaxo-Wellcome, Inc.		
engaged in lobbyin	IVITY. Select as many codes as necessary g on behalf of the client during the reporting tested. Attach additional page(s) as needed.	to reflect the general issue areas in which the registrant g period. Using a separate page for each code, provide	
15. General issue 16. Specific Lobb *Urge FDA t **H.R. 4461:	ying issues	ons for approvat of injectable bioequivalents. reffective pharmaceuticals into the U.S.	
	ongress and Federal agencies contacted Administration resentatives	☐ Check if None	
8. Name of each	individual who acted as a lobbyist in this iss	sue area	
Name		Covered Official Position (if applicable)	New
Baxter, Edwa	rd		No
Davis, Shanne	a		No
DeConcini, De	ПВіз		No
Martin, Jack			No
Parry, Thoma	9		No
Romani, Rom	180		No
Składany, Lin	la		No
	foreign entity in the specific issues listed or	n line 16 above	
	le Romano Romani - President		

Client Name: Glaze-Wellcome, Inc. LOBBVING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Artach additional paget(s) as needed. 15. General issue area code MED. (noe per page) 15. Specific Lobbying issues S-378, Health Care Personal Information Nondisclosures Act of 1999, Interested in maintaining viability of medical and pharaceutical research usder medical records privacy legislation. 3-381, Nealth Care Personal Information Protection Act of 1999, Interested in maintaining viability of medical and pharaceutical research under medical records privacy legislation. 3-381, Nealth Care Personal Information Protection Act of 1999, Interested in maintaining viability of medical and pharaceutical research under medical records privacy legislation. 3-381, Nealth Care Personal Information Protection Act of 1999, Interested in maintaining viability of medical and pharaceutical research under medical records privacy legislation. 3-381, Nealth Care Personal Information and Protection Act of 1999, Interested in maintaining viability of medical and pharaceutical research under medical records privacy legislation. 3-381, Nealth Care Personal Information Protection Act of 1999, Interest of in maintaining viability of medical and pharaceutical research under medical records privacy legislation. 3-381, Nealth Care Personal Information Protection Act of 1999, Interest of in maintaining viability of medical and pharaceutical records privacy legislation. 3-381, Nealth Care Personal Information Protection Act of 1999, Interest of in maintaining viability of medical and pharaceutical records privacy legislation. 3-381, Nealth Care Personal Information Protection Act of 1999, Interest of information protection Act of 1999, Interest of Information Protection Act of 1999, Interest of Information Protection Act of 1999, Interest	OBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the rengaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code aformation as requested. Attach additional page(s) as needed. 5. General issue area code MED (one per page) 6. Specific Lobbying issues 5. S. S. S. Health Care Personal Information Nondisclosure Act of 1999, Interested in maintaining via pharaceutical research under medical records privacy legislation. 5. S. S. S. Medicial Information Protection Act of 1999, Interested in maintaining via pharaceutical research under medical records privacy legislation. 5. S. S. M. Medical Information Protection Act of 1999, Interested in maintaining viability of medical: research under medical records privacy legislation. 5. Support Medicaid coverage of smoking cessation programs. 7. House(s) of Congress and Federal agencies contacted Check if None Food & Drug Administration House of Representatives 8. Name of each individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable) Baxter, Edward DeConcini, Denais Hatch, Scott Martin, Jack Parry, Thomas Romani, Romano Skladany, Linda Interest of each foreign entity in the specific issues listed on time 16 above Check if None	
engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed. General issue area code MED (one per page)	ngaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code formation as requested. Attach additional page(s) as needed. 5. General issue area code MED (one per page) 6. Specific Lobbying issues 5.578, Health Care Personal Information Nondisclosure Act of 1999, Interested in maintaining via pharaceutical research under medical records privacy legislation. 5.881, Medical Information Protection Act of 1999, Interested in maintaining via pharaceutical research under medical records privacy legislation. *Support Medical doverage of smoking cessation programs. 7. House(s) of Congress and Faderal agencies contacted Pood & Drug Administration House of Representatives Senate 8. Name of each individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable) Baxter, Edward DeConcini, Denois Hatch, Scott Martin, Jack Parry, Thomas Romano Skladany, Linda Interest of each foreign entity in the specific issues listed on time 16 above Check if None	
Specific Lobbying issues S.78, Health Care Personal Information Nondisclosure Act of 1999, Interested in maintaining viability of medical and pharaceutical research under medical records privacy legislation. S.881, Medical Information Protection Act of 1999, Interested in maintaining viability of medical and pharaceutical research under medical records privacy legislation. *Support Medical coverage of smoking cessation programs. Check if None Food & Drug Administration Check if None Food & Drug Administration House of Representatives Check if None Food & Drug Administration Senate Covered Official Position (if applicable) New Baxter, Edward No DeContint, Denois No Martin, Jack No No Martin, Jack No No Parry, Thomas No No Romani, Romano No Skladany, Liada No No Skladany, Liada No No Check if None Claxo Wellcome pit NONE Check if None Check if None Claxo Wellcome pit NONE Check if None Check	6. Specific Lobbying issues S.578. Health Care Personal Information Nondisclosure Act of 1999, Interested in maintaining via pharaceutical research under medical records privacy legislation. S.881, Medical Information Protection Act of 1999, Interested in maintaining viability of medical research under medical records privacy legislation. *Support Medicaid coverage of smoking cessation programs. 7. House(s) of Congress and Federal agencies contacted Food & Drug Administration House of Representatives Senate 8. Name of each individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable) Baxter, Edward DeConcini, Denois Hatch, Scott Martin, Jack Parry, Thomas Romano Skladany, Linda Interest of each foreign entity in the specific issues listed on line 16 above Check if None	
S.378, Health Care Personal Information Nondisclosure Act of 1999, Interested in maintaining viability of medical and pharaceutical research under medical records privacy legislation. S.381, Medical Information Protection Act of 1999, Interested in maintaining viability of medical and pharaceutical research under medical records privacy legislation. *Support Medical coverage of smoking cessation programs. 17. House(s) of Congress and Federal agencies contacted Food & Drug Administration House of Representatives 18. Name of each individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable) New Baxter, Edward No DeConcini, Denois No Martin, Jack No Parry, Thomas No Romani, Romano No Skladany, Linda No Interest of each foreign entity in the specific issues listed on line 16 above Check if None Claxo Wellcome pie NONE	S.578, Health Care Personal Information Nondisclosure Act of 1999, Interested in maintaining via phar accutical research under medical records privacy legislation. S.881, Medical Information Protection Act of 1999, Interested in maintaining viability of medical research under medical records privacy legislation. *Support Medicaid coverage of smoking cessation programs. 7. House(s) of Congress and Federal agencies contacted Food & Drug Administration House of Representatives Senate 8. Name of each individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable) Baxter, Edward DeConcini, Denois Hatch, Scott Martin, Jack Parry, Thomas Romano Skladany, Linda	
Food & Orng Administration House of Representatives Senate 18. Name of each individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable) New Baxter, Edward No DeConcint, Denois No Martin, Jack No Parry, Thomas No Romani, Romano No Skladany, Linda No 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None Glaxo Wellcome ptc NONE	Food & Drug Administration House of Representatives Senate 8. Name of each individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable) Baxter, Edward DeConcini, Denais Hatch, Scott Martin, Jack Parry, Thomas Romani, Romano Skladany, Linda	•
Name Covered Official Position (if applicable) New Baxter, Edward No DeConcint, Denois No Batch, Scott No Martin, Jack No Parry, Thomas No SkJadany, Linda No SkJadany, Linda No Interest of each foreign entity in the specific issues listed on line 16 above Glaxo Wellcome pic NONE Date 02/13/2001	Name Covered Official Position (if applicable) Baxter, Edward DeConcini, Dennis Batch, Scott Martin, Jack Parry, Thomas Romani, Romano Skladany, Linda Interest of each foreign entity in the specific issues listed on line 16 above	
DeConcini, Denois Batch, Scott No Martin, Jack Parry, Thomas No Romano Skladany, Linda No Skladany, Linda No Interest of each foreign entity in the specific issues listed on line 16 above Glaxo Wellcome pic NONE Date 62/13/2001	DeConcini, Dengis Batch, Scott Martin, Jack Parry, Thomas Romani, Romano Skladany, Linda Interest of each foreign entity in the specific issues listed on line 16 above Check if None	New
Batch, Scott No Martin, Jack Parry, Thomas No Romani, Romano Skladany, Linda No Interest of each foreign entity in the specific issues listed on line 16 above Glaxo Wellcome pic NONE Date 62/13/2001	Hatch, Scott Martin, Jack Parry, Thomas Romani, Romano Skladany, Linda Interest of each foreign entity in the specific issues listed on line 16 above	No
Martin, Jack Parry, Thomas No Romano Skladany, Linda No Interest of each foreign entity in the specific issues listed on line 16 above Glaxo Wellcome pic NONE Date 02/13/2001	Martin, Jack Parry, Thomas Romani, Romane Skladany, Linda Skladany, Linda Interest of each foreign entity in the specific issues listed on line 16 above	Ne
Martin, Jack Parry, Thomas No Romani, Romane No Skladany, Linda No Interest of each foreign entity in the specific issues listed on line 16 above Glaxo Wellcome pic NONE Date 02/13/2001	Parry, Thomas Romani, Romano Skladany, Linda Interest of each foreign entity in the specific issues listed on line 16 above Check if None	No
Parry, Thomas Romano Romano No Skladany, Linda No Interest of each foreign entity in the specific issues listed on line 16 above Glaxo Wellcome pic NONE Date 02/13/2001	Romani, Romano Skladany, Linda Interest of each foreign entity in the specific issues listed on line 16 above Check if None	No
Romani, Romano Skladany, Linda No Interest of each foreign entity in the specific issues listed on line 16 above Glaxo Wellcome pic NONE Date 02/13/2001	Skladany, Linda Skladany, Linda Interest of each foreign entity in the specific issues listed on line 16 above Check if None	
Skladany, Linda No Interest of each foreign entity in the specific issues listed on line 16 above Glaxo Wellcome ple NONE Date 02/13/2001	Interest of each foreign entity in the specific issues listed on line 16 above Check if None	
9. Interest of each foreign entity in the specific issues listed on line 16 above Glaxo Wellcome ple NONE Date 62/13/2001		
Glaxo Wellcome pic NONE ignature Date62/13/2001		110
		: .
rinted Name and Title Romano Romani - President Page 4 of 5		
	inted Name and Title Romano Romani - President	Page 4 of 5

Client Name:	Parry and Romani Associates, Inc.		
	Giaxo-Welicome, Inc.	_ ^	
engaged in lobbyin	TVTTY. Select as many codes as necessar g on behalf of the client during the report tested. Attach additional page(s) as needed	y to reflect the general issue areas in which the registrant ing period. Using a separate page for each code, provide d.	
16. Specific Lobb	area code <u>TAX</u> (one per page) ying issues tis reporting period.		
(7. House(s) of C	ongress and Federal agencies contacted	X Check if None	
18. Name of each	individual who acted as a lobbyist in this		[xi]
Name	- VIII	issue area Covered Official Position (if applicable)	New
Name Baxter, Edwa	rd		No
Name Baxter, Edwa DeConcini, D	rd		No No
Name Baxter, Edwa DeConcini, D Martin, Jack	rd Pagis		No No
Name Baxter, Edwa BeConcini, Di Martin, Jack Parry, Thoma	rd equis		No No No
Name Baxter, Edwa DeConcini, D Martin, Jack	rd Pagis S S		No No
Name Baxter, Edwa DeConcini, D. Martin, Jack Parry, Thoma Romani, Rom	rd Pagis S S		No No No No No
Name Baxter, Edwa DeConcini, Di Martin, Jack Parry, Thoma Romani, Rom Skiadany, Lin	rd ennis s ano da foreign cnity in the specific issues listed	Covered Official Position (if applicable)	No No No No No